Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 364

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 364
---
,050)                                          ( 1,211)  

Subsidiaries

The business relationships between the Company and its subsidiary Innate Pharma Inc are governed by intra-group agreements, conducted at standard conditions on an arm’s length basis.

20)Income (loss) per share

Basic income (loss) per share

Basic income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period.

                                                                 Year ended December 31.                                                                             
  (in thousands of euro, except for data share)                                     2022                          2023                         2024                  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net income (loss)                                                                            ( 58,103)      ( 7,570)                                    ( 49,471)  
  Weighted average number of ordinary shares in circulation                                   79,639,826                    80,453,282                   81,051,798  
  Basic income (loss) per share (€ per share)                                    ( 0.73)                       ( 0.09)                      ( 0.61)                  

The instruments that entitle their holders to a portion of the share capital on a deferred basis (BSAs, BSAAR, AGAs and AGAPs) are considered to be anti-dilutive ( 2,265,301 5,145,914 5,959,104

F-86

Diluted income (loss) per share

Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential ordinary shares.

                                                                 Year ended December 31,                                                             
  (in thousands of euro, except for data share)                  2022                                             2023      2024                     
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net income (loss)                                                                            ( 58,103)      ( 7,570)                    ( 49,471)  
  Weighted average number of ordinary shares in circulation                                   79,639,826                                 81,051,798  
  Adjustment for share instruments                               —                                                   —      —                        
  Diluted income (loss) per share